Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Response Pharmaceuticals logo — A Clinical Stage (Phase 2) biopharmaceutical company develop...

Response Pharmaceuticals

A Clinical Stage (Phase 2) biopharmaceutical company developing treatments for weight management and metabolic health.

Founded 2022 9 employees Total: $11.90M Biopharma, Biotechnology +1

General Information

Company Name Response Pharmaceuticals
Founded Year 2022
Employees 9
Industries Biopharma, Biotechnology, Pharmaceutical
Business Model B2B, B2C, B2D
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Response Pharmaceuticals. To contact Response Pharmaceuticals, visit responsepharmaceuticals.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Response Pharmaceuticals compare?

A PDF of Response Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Response Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Response Pharmaceuticals

Response Pharmaceuticals is a clinical stage (Phase 2) biopharmaceutical company focused on developing solutions for weight management and metabolic health. Its primary asset, RDX-002, has shown promising results with confirmed efficacy and safety in over 550 subjects. The company is initially targeting a niche opportunity: addressing weight gain and metabolic disturbances in patients on antipsychotic medications—an underserved and growing patient population.

Founded in 2022, Response Pharmaceuticals stands at the intersection of two thriving industries: biopharma and biotechnology. The company’s strategic focus on antipsychotic-induced weight gain tackles a crucial issue within mental health care, offering a potential competitive advantage in the pharmaceutical market.

The company secured a $3.90M Venture Round investment in June 2024, signaling robust investor confidence in their unique approach and product pipeline. Response Pharmaceuticals presents a compelling investment case, leveraging scientific innovation to address significant healthcare gaps.

Business keywords: Clinical Stage Biopharmaceutical, Phase 2 Clinical Development, Weight Management, Metabolic Health, RDX-002, Cardiometabolic Health, Antipsychotic-Induced Weight Gain, Mental Health, AIWG, Drug Efficacy and Safety, Underserved Populations, Psychiatry, Metabolic Dysregulation

Services & Products

Clinical Research and Development
Phase 1 and 2 Clinical Trials
Small Molecule Drug Innovation

Target Customers

Healthcare Providers Patients with Metabolic Disorders Patients Discontinuing GLP-1 Agonists Individuals with Antipsychotic-Induced Weight Gain

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC $3.90M -
01 Jun 2024
Series A $8.00M 1
Stonehaven
01 Feb 2022

Response Pharmaceuticals Alternatives & Competitors

View All Alternatives
Response Pharmaceuticals vs
Verdiva Bio
Verdiva Bio United Kingdom

Transforming lives by accelerating innovation in cardiometabolic health

Series A
78 employees
Biotechnology, Pharmaceutical
Response Pharmaceuticals vs
Lipidio Pharmaceuticals
Lipidio Pharmaceuticals United States

A Unique Approach to Treating Obesity

Series A
5 employees
Biopharma, Biotechnology
Response Pharmaceuticals vs
SyneuRx International (Taiwan) Corp.
SyneuRx International (Taiwan) Corp. Taiwan

Developing new classes of drugs for COVID-19 and multiple major central nervous system disorders.

Post-IPO Equity
12 employees
Biopharma, Pharmaceutical
Also compare with: Response Pharmaceuticals vs Kallyope Kallyope View all alternatives

FAQ About Response Pharmaceuticals

A Clinical Stage (Phase 2) biopharmaceutical company developing treatments for weight management and metabolic health.
Response Pharmaceuticals was founded in 2022.
Response Pharmaceuticals operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Clinical Stage Biopharmaceutical, Phase 2 Clinical Development, Weight Management and Metabolic Health. Its customers include Healthcare Providers, Patients with Metabolic Disorders and Patients Discontinuing GLP-1 Agonists.
Response Pharmaceuticals has a B2B, B2C and B2D business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Response Pharmaceuticals has approximately 9 employees.
Response Pharmaceuticals has completed 2 funding rounds, raising a total of $11.90M.
Response Pharmaceuticals offers: Clinical Research and Development, Phase 1 and 2 Clinical Trials, Small Molecule Drug Innovation.
Top alternatives and competitors to Response Pharmaceuticals include Verdiva Bio, Lipidio Pharmaceuticals, SyneuRx International (Taiwan) Corp., Inventiva Pharma, Septerna. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Response Pharmaceuticals and Verdiva Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Response Pharmaceuticals, https://bouncewatch.com/company/response-pharmaceuticals, updated 3 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout